ROIV - Immunovant gains after Phase 1 data for autoimmune therapy
2023-11-28 15:30:17 ET
More on Immunovant
- Immunovant: Q3 Earnings, Navigating Risks And Rewards In The Autoimmune Arena
- Immunovant: Immune Boost, From Clinical Trials To An Aggressive Bullish Stock
- Immunovant: Data Sizzles, But The Steak Isn't Done Yet (Rating Upgrade)
- Immunovant GAAP EPS of -$0.45 beats by $0.03
- Immunovant to raise $450M from public offering and private placement
For further details see:
Immunovant gains after Phase 1 data for autoimmune therapy